Search results
Results from the WOW.Com Content Network
On Sept. 25, BioAge's stock proceeded with its IPO, which raised gross proceeds of $238.3 million. Before the IPO, it had raised $321 million via several rounds of funding with private investors ...
Biotech stocks are making headlines on Friday as two companies join the public market via initial public offerings (IPOs) today. Source: Shutterstock Let’s dive into the first of the new biotech ...
Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies.
It has been a record-breaking year for new public company listings — including IPOs, direct listings and SPACs — with total U.S. issuance standing at $257 billion.
Samuel D. Waksal (born September 8, 1947) is the founder and former CEO of the biopharmaceutical company ImClone Systems.He is also the founder of Kadmon Pharmaceuticals, which was financed with private capital and commenced operations in New York City in 2010. [1]
Kadmon Corporation (originally Kadmon Pharmaceuticals) is a biopharmaceutical company based in New York City.It also has operations in Warrendale, PA and Brighton, MA.The company was founded in 2009 by Samuel D. Waksal, [2] [3] founder and former CEO of ImClone Systems, a company now fully merged into Eli Lilly.
Some 108 companies conducted their IPO in 2023 and raised $19.4 billion, according to Renaissance Capital. Those figures rose markedly from the 2022 doldrums of 71 IPOs and just $7.7 billion raised.
The following table lists the largest biotechnology and pharmaceutical companies ranked by market capitalization in billion US dollars. The change column indicates the company's relative position in this list compared to their relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.